Minneapolis - St. Paul, Twin Cities, Minnesota & Nationwide
Jury Returns Third Talcum Powder Verdict Against J&J
DIRECT FROM THE COURTROOM IN ST. LOUIS, MISSOURI:
After more than a week of voir dire in the Giannecchini case, ample live testimony has now been provided including the testimony of Dr. Roberta Ness and Mr. David Steinberg.
Otsuka Pharmaceutical Updates Abilify Warning Label
Otsuka Pharmaceutical recently made changes to the Abilify (aripiprazole) label under Warnings and Precautions, Pathological Gambling and Other Compulsive Behaviors (section 5.7).
The scheduling order published on August 11th by the Judicial Panel on Multidistrict Litigation (JPML) included oral arguments for a motion to consolidate talcum powder lawsuits across the nation into a multidistrict litigation (MDL) where all cases would be heard in front of a single judge. Formation of an MDL can minimize duplicative discovery, prevent conflicts in pretrial hearings, and cut litigation costs for all parties involved.
The Judicial Panel on Multidistrict Litigation (JPML) will hear oral arguments in a motion to consolidate the 24 pending Abilify lawsuits, filed in 12 federal district courts across the nation, into a single multidistrict litigation (MDL) for pretrial proceedings.
On May 3, 2016 the FDA issued a warning to physicians, cautioning that the use of Abilify has been linked to compulsive behaviors, including compulsive gambling. For the full text of the warning, click here.
In the recent MDL bellwether trial regarding DePuy Pinnacle metal-on-metal hip
implants, a Northern Texas jury awarded five plaintiffs $502 million in
compensatory and punitive damages against both DePuy and Johnson & Johnson
(DePuy’s parent company). The jury found that the Pinnacle metal-on-metal design
was defective, the company did not provide adequate warnings, and Johnson &
Johnson aided and abetted in fraudulent misrepresentations of the product.